title: Effect of docosahexaenoic acid monoacylglyceride on systemic hypertension and cardiovascular dysfunction.
abstract: ω-3 Fatty acid supplementation has been associated with lower blood pressure. Cardiovascular diseases are also known to be linked directly to an increase in ω-6 and a reduction in ω-3 fatty acid levels in blood circulation and tissues. To determine the effect of docosahexaenoic acid monoglycerides (MAG-DHA) on blood pressure, lipid profiles, and vascular remodeling in rats fed a high-fat/high-carbohydrate (HFHC) diet. Studies were performed in male rats subjected to 8 wk of HFHC diet supplemented or not with 3 g/day MAG-DHA. After 8 wk of daily MAG-DHA treatment, rats in the HFHC + MAG-DHA group had lower arterial blood pressure and heart rate compared with the HFHC group. Moreover, MAG-DHA prevented the increase aortic wall thickness, whereas lipid analysis of aortic tissues revealed an increase in DHA/AA ratio correlated with the production of resolvin D2 and D3 metabolites. Histological analysis revealed that MAG-DHA prevented the development of LVH in the HFHC group. Serum lipid profile analysis further showed a decrease in total cholesterol (TC) and LDL, including very low-density lipoprotein (VLDL) and triglyceride (TG) levels, together with an increase in HDL levels after 8 wk of MAG-DHA treatment compared with the HFHC group. Furthermore, daily MAG-DHA treatment resulted in reduced proinflammatory marker levels such as CRP, IL-6, TNFα, and IL-1β. Altogether, these findings revealed that per os administration of MAG-DHA prevents HFHC-diet induced hypertension and LVH in rats.
authors.affiliation: SCF Pharma, Sainte-Luce, Quebec, Canada; Department of Physiology and Pharmacology, Université de Sherbrooke, Sherbrooke, Quebec, Canada; cmorin@scfpharma.com.
authors.forename: Caroline
authors.initials: C
authors.lastname: Morin
authors.affiliation: Department of Obstetric Gynecology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada, and.
authors.forename: Eric
authors.initials: E
authors.lastname: Rousseau
authors.affiliation: Department of Biology, Université du Québec à Rimouski, Rimouski, Quebec, Canada.
authors.forename: Pierre U
authors.initials: PU
authors.lastname: Blier
authors.affiliation: SCF Pharma, Sainte-Luce, Quebec, Canada; Department of Biology, Université du Québec à Rimouski, Rimouski, Quebec, Canada.
authors.forename: Samuel
authors.initials: S
authors.lastname: Fortin
mesh_terms: D000818:Animals; D001011:Aorta / Q000187:drug effects* / Q000473:pathology; D001794:Blood Pressure / Q000187:drug effects*; D002097:C-Reactive Protein / Q000187:drug effects / Q000378:metabolism; D008076:Cholesterol, HDL / Q000187:drug effects / Q000378:metabolism; D008078:Cholesterol, LDL / Q000187:drug effects / Q000378:metabolism; D015243:Cholesterol, VLDL / Q000187:drug effects / Q000378:metabolism; D059305:Diet, High-Fat; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology; D006352:Heart Ventricles / Q000187:drug effects* / Q000473:pathology; D006973:Hypertension; D017379:Hypertrophy, Left Ventricular / Q000473:pathology; D053583:Interleukin-1beta / Q000187:drug effects / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D050178:Monoglycerides / Q000494:pharmacology*; D051381:Rats; D014280:Triglycerides / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000378:metabolism; D066253:Vascular Remodeling / Q000187:drug effects*
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D015525:Fatty Acids, Omega-3; C000594089:IL1B protein, rat; D053583:Interleukin-1beta; D015850:Interleukin-6; D050178:Monoglycerides; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; C575982:docosahexaenoic acid monoacylglyceride; D002097:C-Reactive Protein
keywords: cardiac hypertrophy; docosahexaenoic acid; hypertension; inflammation